NCT04319757 2024-12-05ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid TumorsAcepodia Biotech, Inc.Phase 1 Completed12 enrolled
NCT05069935 2023-09-21FT538 in Combination With Monoclonal Antibodies in Advanced Solid TumorsFate TherapeuticsPhase 1 Terminated16 enrolled